Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer”

129 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 129 results

Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Testing effectiveness (Phase 2)UnknownNCT04318223
What this trial is testing

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer
Consorzio Oncotech 168
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Looking for participantsNCT07612891
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

Who this might be right for
Breast Cancer (Locally Advanced or Metastatic)Advanced Solid CancersMetastatic (Stage IV) Breast Cancer+2 more
Shenzhen Ionova Life Sciences Co., Ltd.
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Testing effectiveness (Phase 2)Study completedNCT03219476
What this trial is testing

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Who this might be right for
Breast CancerInvasive Breast Cancer
Medical College of Wisconsin 37
Large-scale testing (Phase 3)Active Not RecruitingNCT04305496
What this trial is testing

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 818
Early research (Phase 1)Looking for participantsNCT06756932
What this trial is testing

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Who this might be right for
Hormone-receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
BeOne Medicines 120
Testing effectiveness (Phase 2)Ended earlyNCT02258464
What this trial is testing

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Bayer 99
Early research (Phase 1)Study completedNCT04514159
What this trial is testing

ZN-c5 and Abemaciclib in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Zeno Alpha Inc. 14
Not applicableNot Yet RecruitingNCT06338644
What this trial is testing

Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.

Who this might be right for
Hormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastMetastatic Breast Cancer
Helwan University 100
Not applicableLooking for participantsNCT07546695
What this trial is testing

Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study

Who this might be right for
Breast Cancer
University Hospital, Basel, Switzerland 600
Testing effectiveness (Phase 2)Study completedNCT01441947
What this trial is testing

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 68
Not applicableEnded earlyNCT04967248
What this trial is testing

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Who this might be right for
Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
Novartis Pharmaceuticals 4
Large-scale testing (Phase 3)Study completedNCT03176238
What this trial is testing

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Post Menopausal Breast Cancer
Novartis Pharmaceuticals 235
Very early researchStudy completedNCT04130152
What this trial is testing

Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 22
Large-scale testing (Phase 3)Active Not RecruitingNCT05365178
What this trial is testing

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Who this might be right for
HR-positive, HER2-negative Breast Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 432
Not applicableActive Not RecruitingNCT03904173
What this trial is testing

Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsHormone Receptor Positive Tumor
Oslo University Hospital 2,300
Early research (Phase 1)Looking for participantsNCT06586957
What this trial is testing

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorAdvanced Solid TumorSolid Tumor, Adult+25 more
NiKang Therapeutics, Inc. 150
Load More Results
201